TIRZEPATIDE (40mg)

Tirzepatide is a dual GIP/GLP-1 receptor agonist representing a significant advance over single-receptor GLP-1 therapies. This 40mg presentation provides a high-volume option for extended research protocols or studies requiring multi-week compound supply without frequent reconstitution. Clinical trials have consistently demonstrated superior body weight reduction outcomes compared to all approved GLP-1 monotherapies.

Mechanism of Action

•        Dual GLP-1 and GIP receptor agonism produces synergistic appetite suppression and metabolic improvement in research models.

•        Studied for reductions in postprandial glucose through insulin secretion potentiation and glucagon suppression.

•        Research shows slowed gastric emptying to prolong satiety signals and improve caloric balance.

•        Investigated for beta-cell function preservation in type 2 diabetes models.

Research Areas

•        Extended obesity and overweight pharmacology research.

•        Type 2 diabetes with significant overweight component studies.

•        Cardiovascular risk factor reduction through weight and glycemic biology.

•        Multi-week supply protocols for longitudinal metabolic research.

Presentation and Storage

Supplied as a lyophilized powder in a sealed vial containing 40mg of tirzepatide. Reconstitute with bacteriostatic water for laboratory use. Store at -20C.